The study of Novartis’s Pluvicto in pre-chemo prostate cancer is a bust on overall survival, with questions raised about trial design.

Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.

Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.

Ideaya and GSK join Novartis and Roche in the Werner helicase inhibitor race.

But Repare and Black Diamond still have rebuilding to do.

After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.

Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.

BeiGene regains rights to tislelizumab as another oncology asset blows up for Novartis.